Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;ORAL, RECTAL - 66%;10%
USFDA APPLICATION NUMBER - 11245
DOSAGE - SOLUTION;INTRAUTERINE - 52.7%;26.8%
USFDA APPLICATION NUMBER - 11324
DOSAGE - INJECTABLE;INJECTION - 66%;10%
USFDA APPLICATION NUMBER - 19292
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Diatrizoate Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diatrizoate Meglumine, including repackagers and relabelers. The FDA regulates Diatrizoate Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diatrizoate Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Diatrizoate Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Diatrizoate Meglumine supplier is an individual or a company that provides Diatrizoate Meglumine active pharmaceutical ingredient (API) or Diatrizoate Meglumine finished formulations upon request. The Diatrizoate Meglumine suppliers may include Diatrizoate Meglumine API manufacturers, exporters, distributors and traders.
click here to find a list of Diatrizoate Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Diatrizoate Meglumine DMF (Drug Master File) is a document detailing the whole manufacturing process of Diatrizoate Meglumine active pharmaceutical ingredient (API) in detail. Different forms of Diatrizoate Meglumine DMFs exist exist since differing nations have different regulations, such as Diatrizoate Meglumine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Diatrizoate Meglumine DMF submitted to regulatory agencies in the US is known as a USDMF. Diatrizoate Meglumine USDMF includes data on Diatrizoate Meglumine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Diatrizoate Meglumine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Diatrizoate Meglumine suppliers with USDMF on PharmaCompass.
A Diatrizoate Meglumine written confirmation (Diatrizoate Meglumine WC) is an official document issued by a regulatory agency to a Diatrizoate Meglumine manufacturer, verifying that the manufacturing facility of a Diatrizoate Meglumine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Diatrizoate Meglumine APIs or Diatrizoate Meglumine finished pharmaceutical products to another nation, regulatory agencies frequently require a Diatrizoate Meglumine WC (written confirmation) as part of the regulatory process.
click here to find a list of Diatrizoate Meglumine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Diatrizoate Meglumine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Diatrizoate Meglumine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Diatrizoate Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Diatrizoate Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Diatrizoate Meglumine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Diatrizoate Meglumine suppliers with NDC on PharmaCompass.
Diatrizoate Meglumine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Diatrizoate Meglumine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diatrizoate Meglumine GMP manufacturer or Diatrizoate Meglumine GMP API supplier for your needs.
A Diatrizoate Meglumine CoA (Certificate of Analysis) is a formal document that attests to Diatrizoate Meglumine's compliance with Diatrizoate Meglumine specifications and serves as a tool for batch-level quality control.
Diatrizoate Meglumine CoA mostly includes findings from lab analyses of a specific batch. For each Diatrizoate Meglumine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Diatrizoate Meglumine may be tested according to a variety of international standards, such as European Pharmacopoeia (Diatrizoate Meglumine EP), Diatrizoate Meglumine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diatrizoate Meglumine USP).
LOOKING FOR A SUPPLIER?
